Posted 2 weeks ago

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/​KEYLYNK-013)

ClinicalTrials.gov ID NCT04624204

Protocol number MK7339-013

Sponsor Merck